The VIEW-hub Report captures changes in introduction status and use for the vaccines monitored on VIEW-hub made between December 31, 2024–April 9, 2025.

This toolkit contains messages and graphics highlighting coverage and access data from VIEW-hub that can be shared on social media platforms.

These forest plots summarize available COVID-19 vaccine effectiveness against Omicron variant by vaccine and population of special interest, and for second booster dose and duration of effectiveness. These forest plots are updated regularly.

This plot summarizes the available laboratory evidence on the ability of COVID-19 vaccines to neutralize SARS-CoV-2 variants of concern.

Filterable spreadsheets of vaccine effectiveness studies included in the weekly summary tables. Separate spreadsheets are available for primary series and booster dose studies.

This table summarizes the vaccine effectiveness data for COVID-19 studies conducted globally. This table is updated weekly. 

This table shows the serotypes covered by the current pneumococcal conjugate vaccine products and the three additional products that are in the development pipeline. 

The VIEW-hub Report captures changes in introduction status and use for the vaccines monitored on VIEW-hub made between September 1–December 31, 2024.

The VIEW-hub report displays data and figures on the introduction, use, and coverage status of typhoid conjugate, human papillomavirus, pneumococcal, rotavirus, Hib, and inactivated polio vaccines both globally and in the 54 Gavi countries.

This checklist, intended for researchers, aims to improve comparability, consistency and reliability across SARS-CoV-2 neutralization studies thereby increasing utility for vaccine decision-making.